Trimetazidine Blocks Lipid Oxidation-Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?

Klonoff, David C; Xu, Nicole Y; Nguyen, Kevin T; Kerr, David; Mehta, Chhavi; Umpierrez, Guillermo E; Brooks, George A

Klonoff, David C; Xu, Nicole Y; Nguyen, Kevin T; Kerr, David; Mehta, Chhavi; Umpierrez, Guillermo E; Brooks, George A.

Afiliação

Klonoff DC; Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.
Xu NY; Diabetes Technology Society, Burlingame, CA, USA.
Nguyen KT; Diabetes Technology Society, Burlingame, CA, USA.
Kerr D; Sansum Diabetes Research Institute, Santa Barbara, CA, USA.
Mehta C; Palo Alto Foundation Medical Group, Burlingame, CA, USA.
Umpierrez GE; Emory University, Atlanta, GA, USA.
Brooks GA; Integrative Biology, University of California, Berkeley, Berkeley, CA, USA.

J Diabetes Sci Technol ; 16(5): 1063-1068, 2022 09.

Article em En | MEDLINE | ID: mdl-35652624

Assuntos

Diabetes Mellitus; Cetoacidose Diabética; Trimetazidina; Glicemia; Cetoacidose Diabética/prevenção & controle; Humanos; Lipídeos; Trimetazidina/uso terapêutico

Palavras-chave

SGLT2 inhibitor; ketoacidosis; metabolic modulator; repurpose; trimetazidine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Trimetazidina / Cetoacidose Diabética / Diabetes Mellitus Limite: Humans Idioma: En Revista: J Diabetes Sci Technol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google